Last December the FDA for the first time publicly released data collected by its Center for Food Safety and Applied Nutrition on adverse events related to food and cosmetics since 2004. Before, someone would have had to file a Freedom of Information Act request with the agency to gain access to reports of safety problems.
Hair care products, skin care products and tattoos were most commonly reported as the source of problems, according to the analysis by Xu and colleagues at Northwestern, which was in JAMA Internal Medicine.
The most common complaints, according to Xu, were hair loss or breakage and local skin irritation. Baby products, personal cleanliness products, and hair care and coloring products were found to have the highest proportion of serious adverse events, including serious injuries, hospitalization and death.
From 2015 to 2016, the number of reported adverse events more than doubled. This leap, Xu says, was driven largely by complaints of hair loss and skin irritation associated with WEN by Chaz Dean Cleansing Conditioners. In 2014, the FDA announced that it was investigating WEN products.
Although the FDA had received only 127 complaints about these products by that time, the manufacturer had received about 21,000 complaints, according to the FDA. Unfortunately, manufacturers have no legal obligation to report adverse events to the FDA. So the FDA has asked the public to submit complaints about WEN conditioners directly to the agency. Many of the 2016 complaints, says Xu, were a direct result of that call to action. The agency also welcomes reports on problems with other personal care products through its online MedWatch system.
Guthy-Renker, the marketing company behind WEN products, said in a statement to NPR after the story published, “We welcome legislative and regulatory efforts to further enhance consumer safety across the cosmetic products industry. However, there is no credible evidence to support the false and misleading claim that WEN products cause hair loss.”
In an editorial also published in JAMA Internal Medicine, former FDA Commissioner Robert M. Califf and his co-authors say there needs to be better premarket assessment and post market surveillance of cosmetic products. Substantial improvements to cosmetics regulations, they say, would require more support for the “chronically underfunded” FDA, mandatory registration of cosmetic products, and modernization of cosmetics oversight, based on systems the FDA already has in place for drug and device monitoring. With these changes, they write, “we can achieve the high levels of safety people in the United States have a right to expect.”